Thursday, July 31, 2014

If you pick one over the other

you are a criminal or don't care about NY Const. Art. 1, Sec. 3.


N.Y. / Region

U.S. Attorney Warns Cuomo on Moreland Commission Case


Continue reading the main story Share This Page
In an escalation of the confrontation between the United States attorney in Manhattan, Preet Bharara, and Gov. Andrew M. Cuomo over the governor’s cancellation of his own anticorruption commission, Mr. Bharara has threatened to investigate the Cuomo administration for possible obstruction of justice or witness tampering.
The warning, in a sharply worded letter from Mr. Bharara’s office, came after several members of the panel issued public statements defending the governor’s handling of the panel, known as the Moreland Commission, which Mr. Cuomo created last year with promises of cleaning up corruption in state politics but shut down abruptly in March.
Mr. Bharara’s office has been investigating the shutdown of the commission, and pursuing its unfinished corruption cases, since April.
In the letter, sent late Wednesday afternoon to a lawyer for the panel, prosecutors alluded to a number of statements made by its members on Monday, which generally defended Mr. Cuomo’s handling of the commission. The statements were released on the same day Mr. Cuomo first publicly responded to a report in The New York Times that described how he and his aides had compromised the commission’s work.

Photo

Gov. Andrew M. Cuomo Credit Dominic Nahr for The New York Times

At least some of those statements were prompted by calls from the governor or his emissaries, according to people with direct knowledge of the situation who were unwilling to be named for fear of reprisal.
One commissioner who received a call from an intermediary on behalf of the governor’s office said he found the call upsetting and declined to make a statement.
The letter from prosecutors, which was read to The New York Times, says, “We have reason to believe a number of commissioners recently have been contacted about the commission’s work, and some commissioners have been asked to issue public statements characterizing events and facts regarding the commission’s operation.”
“To the extent anyone attempts to influence or tamper with a witness’s recollection of events relevant to our investigation, including the recollection of a commissioner or one of the commission’s employees, we request that you advise our office immediately, as we must consider whether such actions constitute obstruction of justice or tampering with witnesses that violate federal law.”
Reached late Wednesday night, a spokesman for the governor did not immediately respond to a request for comment on the letter from Mr. Bharara’s office. A lawyer for the commission declined to comment on the letter.
The Times reported last week that Mr. Cuomo’s office had deeply compromised the panel’s work, objecting when it focused on groups with political ties to Mr. Cuomo, a Democrat who is seeking re-election, or on issues that might reflect poorly on him.

Photo

Preet Bharara, the United States attorney in Manhattan. Credit Anthony Lanzilote for The New York Times

The Times’s article prompted condemnations from government watchdog groups and newspaper editorial boards. Mr. Cuomo, facing perhaps the harshest scrutiny of his three and a half years as governor, remained out of public view for five days as criticism mounted.  
Late Sunday night, Mr. Cuomo’s office announced that he would make an appearance in Buffalo on Monday morning, setting in motion what appeared to be a coordinated effort by Mr. Cuomo and his aides to present a defense for their conduct.
Just hours before Mr. Cuomo faced reporters, one of the co-chairs of the commission, William J. Fitzpatrick, released a three-page statement in which he asserted that “nobody ‘interfered’ with me or my co-chairs.”
Facing questions from the news media, Mr. Cuomo repeatedly cited the statement by Mr. Fitzpatrick, the Onondaga County district attorney. The governor called the statement “very helpful,” explaining that Mr. Fitzpatrick “knows better than anyone else what happened with the Moreland Commission.”
“Now we have facts that we can actually deal with, right?” Mr. Cuomo said.
Mr. Fitzpatrick’s statement seemed at odds with frustration he had expressed to colleagues last year; in one email reported by The Times, he wrote that Mr. Cuomo’s office “needs to understand this is an INDEPENDENT commission and needs to be treated as such.” Mr. Cuomo dismissed that email as “snippets of conversations.”

Continue reading the main story

Timeline: The Short Life of an Anticorruption Commission


Mr. Fitzpatrick’s statement on Monday also appeared to contradict previous statements he made to federal prosecutors, according to three people briefed on the matter but not authorized to speak on the record.  Mr. Fitzpatrick did not immediately return a call late Wednesday seeking comment.
Also Monday, Thomas P. Zugibe, the Rockland County district attorney and a commission member, released a statement in which he asserted that the panel “did incredible work” and said, “At all times it was clear that all investigatory decisions were within the exclusive discretion of the Commission.”
Another commission member, Frank A. Sedita III, the Erie County district attorney, issued a statement that acknowledged there had been “rumors” that Mr. Cuomo’s office had sought to block the issuance of some subpoenas. But he said that Mr. Cuomo’s office ultimately “agreed not to interfere with our work.”
And in an interview with Gannett, Gerald F. Mollen, the Broome County district attorney, said he believed that he and his colleagues had “absolute independence to go wherever the commission wanted and the governor could not stop us if we choose to go somewhere.”
The letter noted “the commissioners and the commission’s employees are important witnesses in this ongoing investigation, and information from those with personal knowledge of facts of the investigation is highly material to that investigation.”
The letter warned that tampering with the recollections of commission members or employees could be a crime, and directed them to preserve any records of “actual or attempted contact” along those lines.
James Margolin, a spokesman for the United States attorney’s office, declined to comment Wednesday night.



HI-
Thanks for the help. The item’s below. I’d be happy to mail you a copy, if you give me a mailing address.

Claude Solnik
(631) 913-4244
Long Island Business News
2150 Smithtown Ave.
Ronkonkoma, NY 11779-7348 

Home > LI Confidential > Stop scratching on holidays

Stop scratching on holidays
Published: June 1, 2012


Off Track Betting in New York State has been racing into a crisis called shrinking revenue. Some people have spitballed a solution: Don’t close on holidays.
New York State Racing Law bars racing on Christmas, Easter and Palm Sunday, and the state has ruled OTBs can’t handle action on those days, even though they could easily broadcast races from out of state.
“You should be able to bet whenever you want,” said Jackson Leeds, a Nassau OTB employee who makes an occasional bet. He added some irrefutable logic: “How is the business going to make money if you’re not open to take people’s bets?”
Elias Tsekerides, president of the Federation of Hellenic Societies of Greater New York, said OTB is open on Greek Orthodox Easter and Palm Sunday.
“I don’t want discrimination,” Tsekerides said. “They close for the Catholics, but open for the Greek Orthodox? It’s either open for all or not open.”
OTB officials have said they lose millions by closing on Palm Sunday alone, with tracks such as Gulfstream, Santa Anita, Turf Paradise and Hawthorne running.
One option: OTBs could just stay open and face the consequences. New York City OTB did just that back in 2003. The handle was about $1.5 million – and OTB was fined $5,000.
Easy money.

Wednesday, July 30, 2014

Aetna and MS



Aetna does not care that BCG works for MS and other things, thus calling into question the quality of their thinking, even if said thinking is driven only by money.

Ristori for healthcare minister of the US or Governor of NY?




Business

Aetna's Profit Rises Despite Higher Medical Costs

Insurer Cites New Hepatitis Treatments, Public Exchanges for Growing Expenses


Updated July 29, 2014 11:12 a.m. ET
Aetna Inc. AET -2.61% said its second-quarter profit rose as the insurer posted record medical membership and revenue, but shares declined over concerns about its rising medical costs.
Aetna's total medical benefit ratio—the amount of premiums used to pay patient medical costs—was 83.1% in the second quarter, up from 82.5% a year earlier and above analyst expectations. The company tied the increase in part to costs from new hepatitis C treatments and its public-exchange membership.
Chief Financial Officer Shawn M. Guertin said in an interview that the cost of hepatitis C treatments continued to accelerate in the second quarter but appeared to plateau toward the end of the period. The insurer expects costs for treatments for the liver disease to be up next year and is factoring that into its pricing for 2015 plans.
Meanwhile, Aetna said it had nearly 600,000 health-law marketplace members at the end of the second quarter, though it expects the number to drop to a little more than 500,000 by the end of the year due to attrition. The insurer, which is selling plans in 16 states and the District of Columbia, said it will likely add one more next year, Georgia.
Aetna said the overall individual business will amount to a "modest headwind" to earnings this year. Mr. Guertin said Aetna expects the new enrollees under the Affordable Care Act to "have higher costs and higher utilization" than other commercial-plan members. But so far it appears to be "in the neighborhood of our pricing assumptions," he said.
Aetna said it isn't seeing a lot of small businesses dumping employees into the public marketplaces so far. Mr. Guertin said Aetna believes that dumping will "break along industry lines" over time, with more occurring in businesses with lower-wage workers who could benefit from federal subsidies. However, the "pace and the degree of dumping is still an open question," he said.
Overall, Aetna said it continues to "experience moderate medical cost trends" and projected the medical costs from its commercial plans would come in at the low end of its projected range for 6% to 7% growth.
"The lowering of the cost trend outlook to the bottom-half of the 6%-7% prior range should somewhat help ameliorate concerns regarding the commercial medical care ratio," Sterne Agee analyst Brian Wright said.
Aetna shares, up 34% over the past year, declined as much as 3.3% in early trading.
The company also raised its earnings outlook for the year by 10 cents on the lower end of its previous range and by five cents on the higher end to $6.45 to $6.60 a share.
In addition, Aetna increased its expectations for accretion from its acquisition of Coventry Health Care Inc., now seeing 55 cents to 60 cents a share in additional benefits, up five to 10 cents from its previous range.
Overall, Aetna posted quarterly earnings of $548.8 million, or $1.52 a share, up from $536 million, or $1.49 a share, a year earlier. Excluding items such as costs related to the Coventry deal, per-share operating earnings rose to $1.69 from $1.62.
Operating revenue, which excludes net realized capital gains and losses, increased 25% to $14.49 billion, mostly from higher premiums from about one additional month of revenue from the Coventry deal.
Analysts had projected earnings of $1.60 a share and revenue of $13.99 billion, according to Thomson Reuters.
The company had total medical membership of 23.1 million as of March 31, up from 22.72 million in the prior quarter and 22 million a year earlier.
Write to Michael Calia at michael.calia@wsj.com


Results: 6

1.
Ristori G, Romano S, Cannoni S, Visconti A, Tinelli E, Mendozzi L, Cecconi P, Lanzillo R, Quarantelli M, Buttinelli C, Gasperini C, Frontoni M, Coarelli G, Caputo D, Bresciamorra V, Vanacore N, Pozzilli C, Salvetti M.
Neurology. 2014 Jan 7;82(1):41-8. doi: 10.1212/01.wnl.0000438216.93319.ab. Epub 2013 Dec 4.
PMID:
24306002
[PubMed - indexed for MEDLINE]
2.
Paolillo A, Buzzi MG, Giugni E, Sabatini U, Bastianello S, Pozzilli C, Salvetti M, Ristori G.
J Neurol. 2003 Feb;250(2):247-8. No abstract available.
PMID:
12622098
[PubMed - indexed for MEDLINE]
3.
Rook GA, Ristori G, Salvetti M, Giovannoni G, Thompson EJ, Stanford JL.
Immunol Today. 2000 Oct;21(10):503-8. Review. No abstract available.
PMID:
11071529
[PubMed - indexed for MEDLINE]
4.
Ristori G, Buzzi MG, Sabatini U, Giugni E, Bastianello S, Viselli F, Buttinelli C, Ruggieri S, Colonnese C, Pozzilli C, Salvetti M.
Neurology. 1999 Oct 22;53(7):1588-9.
PMID:
10534275
[PubMed - indexed for MEDLINE]
5.
Henderson DA, Labusquire R, Nicholson CC, Rey M, Ristori C, Dow PJ, Saroso JS, Millar JD.
Paediatr Indones. 1972 Oct;12(10):409-26.
PMID:
4679478
[PubMed - indexed for MEDLINE]
6.
Ristori C.
Bol Oficina Sanit Panam. 1969 May;66(5):436-49. Spanish. No abstract available.
PMID:
4239683
[PubMed - indexed for MEDLINE]
 

African corpses supply

drone makers around the world with  payload?

United States biological defense program - Wikipedia, the ...

en.wikipedia.org/.../United_States_biological_defense_progra...
Wikipedia
The laboratory at Pine Bluff Arsenal, Arkansas, was converted to a toxicological ... During the 1995 outbreak of Ebola fever in Zaire, the AIT remained on alert to ...

Jeri Burtchell

what does she have to say about the work of Ristori et al?
is she aware of the same?
does she love Norvartis' dope/cash?
life, death, holes in the brain, it is all the same?

U.S. News

Researchers Fret as Social Media Lift Veil on Drug Trials

Online Chatter Could Unravel Carefully Built Construct of 'Blind' Clinical Trials

July 29, 2014 10:30 p.m. ET
Jeri Burtchell at home in East Palatka, Fla. Bob Croslin for The Wall Street Journal
On her first day in a clinical trial for an experimental multiple sclerosis drug, Jeri Burtchell was convinced she was getting the new drug, not the standard therapy that some patients were randomly assigned to receive.
When she bumped into the trial's lead investigator in the elevator that day, she told him, "I think I know which drug I'm on!" The doctor put up his hands, waving her off. "Don't tell me!" Ms. Burtchell recalls him blurting. "I can't know!"
A nurse later explained to her that knowing who was getting what could compromise the research. Even so, Ms. Burtchell went home and recounted the incident to followers of a blog she was writing about the trial. "The mystery medicine is doing its job," she wrote.
For decades, the clinical trials vital to developing new drugs have followed a central principle: Researchers and patients must both be "blinded" as to who is getting the experimental drug and who a placebo or standard therapy.
If patients know who has the new drug, or learn too much about how others in the trial are faring, this knowledge could influence how they report symptoms and make it hard to tell whether the drug is working. Staying in the dark throughout a trial is a standard held sacrosanct by researchers. But lately, not so much by patients.
On Facebook groups, online forums and blogs, some patients are effectively jeopardizing the blind. In trials for hepatitis C, multiple sclerosis and ALS (Amyotrophic lateral sclerosis, also known as Lou Gehrig's disease), patients have been sharing details of their reactions and trying to figure out whether they are getting the active drug.
Patients also swap tips on how to get accepted into trials, even if they don't meet all the requirements. Some who are in trials collect and analyze their medical data and others' to get an early indication of whether a drug will be a success.
Drug makers and researchers are increasingly concerned that online chatter could unravel the carefully built construct of the clinical trial, and perhaps put patients in danger. They worry that patients may drop out if they suspect they aren't getting the drug being tested, or may report symptoms inaccurately because of the influence or suggestions of others in the trial.
Patients who share too much "could effectively chill a new drug before it ever gets to patients by misinterpreting early signals," says Craig H. Lipset, head of clinical innovation at Pfizer Inc., PFE -0.71% who wrote an opinion piece in Nature Medicine in March calling on trial sponsors and regulators to study the effects of social media. "It's scary."
Patients, for their part, often say they have the right to talk about their experiences. In life-threatening diseases such as ALS, patients "want, need and deserve to know" how others are doing, says April Moundzouris, a Chattanooga, Tenn., woman whose "April's ALS Blog" chronicles her experience with an experimental stem-cell treatment. The early-stage research by Neuralstem Inc. CUR -3.81% isn't blinded.
Neuralstem Chief Executive I. Richard Garr , a close reader of April's blog and those of other patients, says the sharing may pose a challenge later on when it comes time for a trial designed to prove efficacy to the Food and Drug Administration. That trial would likely have to be blinded.
A patient who blogs that he or she isn't feeling well, isn't improving or has some symptom can sway how other patients report or their willingness to join a trial, Mr. Garr says.
This is just one of the ways the Internet and social media bear on the drug-discovery process. Richard Bedlack, who runs the ALS clinic at Duke University, is involved in a project that asks patients to tweet tips about alternative and off-label treatments that he and other doctors assess to see if they might make promising research candidates.

Excerpt from a post on Jeri Burtchell's blog

"(The nurse) tells me the shot should go in the outer half of my thigh, somewhere in the center 1/3. I didn't know I was going to have to be good at fractions to be able to do this, but I listen to her and nod like I'm understanding it all. She wipes with alcohol, and the next thing I know I'm seeing that big needle sink into my thigh like I was the Pillsbury dough boy's sister. It went right in with no effort at all and I couldn't even feel it. She pushed the plunger and I braced myself for a sting or burn as the medicine hit my muscle, but…nothing. It was at that point that I'm thinking "hey!! I bet that was just water!!: which means I can quit worrying about Avonex side effects and worry about Fingolimod ones.''
By contrast, some pharmaceutical companies have tried to avoid using social media so they won't learn about something that might make clinical analysis of an experiment more challenging or might have to be reported to FDA, according to Joseph Kim, an executive at Irish drug maker Shire SHPG +0.18% PLC.
Says Mr. Garr: "The FDA is going to have to figure out how to accommodate social media."
A spokeswoman for the FDA says the agency doesn't have a policy on subjects in trials using social media to communicate with one another.
PatientsLikeMe, a Cambridge, Mass., company that runs a patient network and research platform where patients share health information, including during clinical trials, is wrestling with how to address the effects the constant sharing of information can have on trials.
In a 2012 paper, Paul Wicks of PatientsLikeMe wrote that according to the company's data, a little more than 400 patients on the site have added treatment information that shows they are on a clinical trial. If patients start trying to determine if they are receiving the new drug, he asked, "how should we respond to this as researchers or as a company?" Dr. Wicks says the company is trying to get patients and researchers to work together to design trials, believing that collaboration will lead to better understanding of the issues.
To date, no clinical trial has been stopped because of online sharing of patients' experiences. But drug makers are starting to take pre-emptive steps.
Shire helped create educational videos about the consequences of sharing too much, working with a Boston-based nonprofit called the Center for Information and Study on Clinical Research Participation. In one animated video, a blue bean's description of side effects from a drug causes a yellow bean to drop out of a study. Shire, whose board has agreed to a takeover by AbbVie Inc., ABBV +0.60% tells patients how to download the videos.
"The industry needs to do a lot more,'' says Shire's Mr. Kim, director of patient recruitment and engagement. "It is a hard thing to modify behavior without it being too controlling."
Vertex Pharmaceuticals Inc. VRTX -3.71% was testing a drug for hepatitis C when Lindsay McNair, then its senior medical director, got an alert from an investigator that patients in the trial were posting about it. She went to MedHelp.org, a site that hosts patient message boards, and started reading. "They were really incredible threads," she says.
One patient advised those who wanted to know whether they were getting the experimental drug to ask a doctor not involved in the trial for a test of viral load. If it had dropped dramatically, the patient wrote, that was a sign the person was getting the new drug, because standard therapy wouldn't have such an effect. Some patients discussed dropping out if they concluded they weren't getting the new drug. (Some did quit the trial, though it isn't known if online sharing was a factor.)
Dr. McNair discussed the posts with others at the Boston-based company. They were concerned about patients harming their health by not reporting symptoms out of concern they could be taken off the trial. If enough dropped out, it might be hard to get an adequate test of the drug, says Dr. McNair, now chief clinical research officer at WIRB-Copernicus Group, which provides regulatory and ethical reviews of research.
So for its next trial, Vertex added an unusual paragraph to the consent document for subjects, explaining that rumors about side effects or about the drug's efficacy might affect results and require doing the study over. Participants should feel free to discuss their participation with family, friends and medical providers, the paragraph said, but not publicly such as in Internet message boards.
"It was meant to be informational and educate about the implications discussions could have, but not to say they can't talk or there would be repercussions if they did,'' says Dr. McNair.
Not all the patients understood this. One who signed the document then posted on the MedHelp Hepatitis C forum: "There's no specific legal recourse spelled out, but there is another section that states that my participation in the study can be ended at any time without my permission." The patient wrote that the forum provided him with important information about managing his disease and about the trial. "I hope people will still talk to me here?!" he added.
Vertex says oversharing on social media isn't grounds for eviction from a study. It continues to warn about the problem in consent forms. Vertex says there was no effort to identify or remove from the trial the person who posted on the MedHelp forum.
The hepatitis C drug won FDA approval, and now is sold as Incivek, but "the experience was nerve-racking," Dr. McNair says.
Dr. Bedlack of Duke says the information patients share online can turn out to be incorrect. Before revealing the drug information at the conclusion of a trial, he often asks patients to guess whether they got active drug. "Most times they don't get it right," he says.
Ms. Burtchell, the multiple sclerosis patient, did guess right.
Now a 53-year-old resident of East Palatka, Fla., she was diagnosed in 1999 with the kind of MS that involves relapses interspersed with remission. By 2007 she estimates she had suffered nearly 30 relapses and was so exhausted she had difficulty caring for her young son.
She enrolled in a trial for an experimental therapy from Novartis AG NOVN.VX +0.44% that aimed to be the first pill for the disease, which was treatable only with injectable drugs. The trial matched one of injectable therapy, Avonex, against the experimental oral drug, called fingolimod.
Ms. Burtchell started a blog to chronicle her experience from start to finish. In the post after her first treatment, she told why she believed she was getting fingolimod.
In the past, she had taken injections for her condition. In the trial, she didn't feel the stinging or pain she remembered from shots—a sign, she believed, that her injection in the trial was a placebo.
Also, after she was given a pill, she noticed a nurse recorded a fall in her blood pressure, which she knew was a potential side effect of the experimental drug.
Nearly three months into the trial, Ms. Burtchell posted that, for the first time since her MS diagnosis, she was able to hop on one foot.
"Maybe it's the Fingolimod…," she speculated. "Whatever it is, I feel better every day."
When information on the study was revealed, it turned out she was indeed getting the experimental drug.
A spokesman for Novartis says consent forms for its trials don't prohibit patients from talking about their trial participation. The spokesman says the company didn't interact with Ms. Burtchell during the trial.
The drug was approved by the FDA in 2010 and now is sold as Gilenya. Novartis continued to study it in nonblinded research, in which Ms. Burtchell participated. Eventually, she served for a time as a paid speaker for Novartis, sharing her experiences.
She also continued to blog.
One of her followers was Pfizer's Mr. Lipset, who was interested in how patients use social media.
In September 2011, he sent her a message on Twitter asking to talk. Mr. Lipset says he wanted to discuss the downsides of patients comparing notes. They talked, and each saw the other's side.
Mr. Lipset says Ms. Burtchell helped him realize that "it's not the patients who will change, but the researchers who have to change." She reminded him, he says, that "ultimately patients are human beings. They are going to talk."
In Ms. Burtchell's post after their talk, she conceded that the Pfizer executive had made many good points. Even so, she concluded, "If I'm going to be poked and prodded, I'm going to be here blabbing about it."
Later, her views started to shift. In 2012, Mr. Lipset invited her to appear on stage with him at a pharmaceutical-industry conference in Boston. She was asked if she ever worried about influencing others in a trial. "I think that is when the realization of what I had done really hit me," she says.
At a February drug-industry conference in Miami where she was asked to speak about patients and social media, Ms. Burtchell proposed her own solution: that drug companies create online forums where patients can get practical questions answered by investigators and can commiserate with other patients about social issues in a moderated setting. She set up Partners in Research, a website that guides patients through the clinical-trials process.
She continues to take Gilenya for her MS and has had two relapses while on it, most recently in February. She is part of a study looking at its long-term effects.
But she has stopped her blog.
"I'm too aware of the impact,'' she says, "too conscious of my audience, to blog like that again."
Write to Amy Dockser Marcus at amy.marcus@wsj.com



see also faustmanlab.org
and pubmed.org faustman dl

Results: 6

1.
Ristori G, Romano S, Cannoni S, Visconti A, Tinelli E, Mendozzi L, Cecconi P, Lanzillo R, Quarantelli M, Buttinelli C, Gasperini C, Frontoni M, Coarelli G, Caputo D, Bresciamorra V, Vanacore N, Pozzilli C, Salvetti M.
Neurology. 2014 Jan 7;82(1):41-8. doi: 10.1212/01.wnl.0000438216.93319.ab. Epub 2013 Dec 4.
PMID:
24306002
[PubMed - indexed for MEDLINE]
2.
Paolillo A, Buzzi MG, Giugni E, Sabatini U, Bastianello S, Pozzilli C, Salvetti M, Ristori G.
J Neurol. 2003 Feb;250(2):247-8. No abstract available.
PMID:
12622098
[PubMed - indexed for MEDLINE]
3.
Rook GA, Ristori G, Salvetti M, Giovannoni G, Thompson EJ, Stanford JL.
Immunol Today. 2000 Oct;21(10):503-8. Review. No abstract available.
PMID:
11071529
[PubMed - indexed for MEDLINE]
4.
Ristori G, Buzzi MG, Sabatini U, Giugni E, Bastianello S, Viselli F, Buttinelli C, Ruggieri S, Colonnese C, Pozzilli C, Salvetti M.
Neurology. 1999 Oct 22;53(7):1588-9.
PMID:
10534275
[PubMed - indexed for MEDLINE]
5.
Henderson DA, Labusquire R, Nicholson CC, Rey M, Ristori C, Dow PJ, Saroso JS, Millar JD.
Paediatr Indones. 1972 Oct;12(10):409-26.
PMID:
4679478
[PubMed - indexed for MEDLINE]
6.
Ristori C.
Bol Oficina Sanit Panam. 1969 May;66(5):436-49. Spanish. No abstract available.
PMID:
4239683
[PubMed - indexed for MEDLINE]

BCG and Autoimmunity Working Group Publishes First Book ...

www.businesswire.com/.../BCG-Autoimmunity-Working-Group-Publish...
Apr 22, 2014 - The BCG and Autoimmunity Working Group publish first book, ... of BCG and TNF in Autoimmunity, edited by Denise Faustman, MD, PhD, ...

BCG and Autoimmunity Working Group Publishes ... - Reuters

www.reuters.com/.../ma-bcg-autoimmunity-grp-idUSnBw226373...
Reuters
Apr 22, 2014 - ... Working Group Publishes First Book “The Value of BCG and TNF in ... as more members join the working group,” said Dr. Faustman. BCG is ...

Andrew & Mario Cuomo Crimes

include allowing Nassau OTB to close on Roman Catholic Palm Sunday and Easter Sunday in preference to Greek Orthodox Palm Sunday and Easter Sunday. Wanting to work and/or bet is a crime in NY. Secret
Agent Christopher Wright is a former Director of Nassau OTB who helped allow Nassau OTB to bet your $23,000,000 on the Nassau OTB Race Palace when many many many... told OTB it was a BAD BET.

NY Const. Art. 1, Sec. 3 say that Andrew Cuomo is not the holy one blessed be he.

Nassau faces $77 million cash deficit, county comptroller says

Nassau County Comptroller George Maragos on June 12,
Nassau County Comptroller George Maragos on June 12, 2013. (Credit: Howard Schnapp)
County Comptroller George Maragos projected Tuesday that Nassau will end the year with a nearly $77 million cash deficit, primarily due to a steep decline in sales tax revenues and increasing costs of police overtime.
Maragos also said in his midyear budget report, required by the county charter, that the difference between recurring revenues and recurring expenses -- the structural budget gap -- will increase to $242 million by the close of this year, after dropping to $99 million last year.
Maragos said fellow Republican County Executive Edward Mangano and the county's financial control board, the Nassau Interim Finance Authority, must take "immediate steps" to close the deficit to "avoid the unpleasant consequences that will arise from our projections, should they be allowed to materialize."

SEARCH: Nassau County salaries | Nassau County overtime | Nassau County raises | LI town and city payrolls
MORE: Nassau County property tax refunds

Tim Sullivan, Mangano's deputy county executive for finance, said the administration already has submitted a plan to NIFA to reduce overtime spending through "management initiatives" and by cutting funds budgeted for supplies, equipment and contractual expenses.
Sullivan said the county has asked for proposals from an independent economic consultant to review and report on the sales tax data by Sept. 5. The administration had questioned the accuracy of the state's allocation of sales tax revenues, after Nassau's collections dropped by 9 percent through June compared with the same period last year.
The county charter requires Mangano to submit his proposed 2015 budget on Sept. 15.
Maragos projects that police overtime will cost $67.4 million this year compared to $50 million budgeted. He also predicts a $90 million shortfall in sales tax revenues, which he said reflects slower economic activity after a surge in spending after superstorm Sandy in 2012, and a shift to online shopping.
Sullivan is projecting a $51 million sales tax shortfall but says changes in police contracts that restrict the use of leave time, along with the hiring of new police officers at a lower pay scale, will slow the growth in overtime.
NIFA recently lifted a three-year wage freeze on four of the county's five major unions after they negotiated new contracts that the administration and labor leaders said will save tens of millions of dollars in future years. NIFA is expected to approve a new deal for county correction officers next month.
NIFA chairman Jon Kaiman had asked Nassau to develop new revenues to cover immediate costs projected at about $130 million over four years.
Sullivan, in a memo to NIFA, said some of those initiatives, such as increased fees and new speed cameras in school zones, will help close this year's projected deficit.
The county also plans to borrow to pay $25 million in employee termination costs and $75 million in tax refunds before a new commercial refund system takes effect in 2017. He predicts the county will end this year with a $10 million cash surplus.
Kaiman could not be reached for comment.
NIFA member Chris Wright, who warned that the new union deals would cost more than anticipated, called Maragos' projected $76.9 million cash deficit "unfortunate, but not surprising. It's exactly what was to be expected -- and was predicted by objective analysts -- when the county added substantially to its cost base in the face of declining revenues. That the county did so with NIFA's approval compounded the error."
Wright was the only NIFA board member to vote against the four union deals approved so far.




 HI-

Thanks for the help. The item’s below. I’d be happy to mail you a copy, if you give me a mailing address.



Claude Solnik

(631) 913-4244

Long Island Business News

2150 Smithtown Ave.

Ronkonkoma, NY 11779-7348



Home > LI Confidential > Stop scratching on holidays
Stop scratching on holidays
Published: June 1, 2012

Off Track Betting in New York State has been racing into a crisis called shrinking revenue. Some people have spitballed a solution: Don’t close on holidays.

New York State Racing Law bars racing on Christmas, Easter and Palm Sunday, and the state has ruled OTBs can’t handle action on those days, even though they could easily broadcast races from out of state.

“You should be able to bet whenever you want,” said Jackson Leeds, a Nassau OTB employee who makes an occasional bet. He added some irrefutable logic: “How is the business going to make money if you’re not open to take people’s bets?”

Elias Tsekerides, president of the Federation of Hellenic Societies of Greater New York, said OTB is open on Greek Orthodox Easter and Palm Sunday.

“I don’t want discrimination,” Tsekerides said. “They close for the Catholics, but open for the Greek Orthodox? It’s either open for all or not open.”

OTB officials have said they lose millions by closing on Palm Sunday alone, with tracks such as Gulfstream, Santa Anita, Turf Paradise and Hawthorne running.

One option: OTBs could just stay open and face the consequences. New York City OTB did just that back in 2003. The handle was about $1.5 million – and OTB was fined $5,000.

Easy money.

Monday, July 28, 2014

kevin tracey v the alternative

Dear Patients of Kevin J Tracey:
  I commend to your attention the work of Dr. Denise L Faustman et al. See eg pubmed.org faustman dl and pubmed.org ristori + BCG.  A useful treatment for autoimmune diseases is to increase the level of TNF alpha rather than decrease it. As many auto mechanics et al know, BCG is safe and inexpensive just like ammunition and munitions. If Sergey Brin wanted to cure autoimmune diseases, Faustman would simply manufacture a peptide and give it to willing volunteers.

I am available to be shot on You Tube with BCG which I have found to be safe and effective for plaque psoriasis. In severe cases of psoriasis, the cardiovascular damage that occurs may be easily reduced by shooting BCG.

Kevin J. Tracey aspires to be a corporation, a person without a soul.  Engage him in debate and discussion and let him practice his art on his immediate family.





Opinion

Let Patients Decide How Much Risk They'll Take

Take a tip from Sergey Brin: The health-care regulatory burden stops entrepreneurs from getting into the game.




  •  
  • Updated July 27, 2014 6:44 p.m. ET
    Earlier this month, at a private conference for the CEOs of his portfolio companies, venture capitalist Vinod Khosla interviewed Google GOOGL +0.16% co-founders Sergey Brin and Larry Page, asking them if the company might jump into health care. "It's just a painful business to be in," Mr. Brin replied, later noting that "the regulatory burden in the U.S. is so high that I think it would dissuade a lot of entrepreneurs."
    Mr. Brin is right. As a neurosurgeon-scientist and entrepreneur who co-founded a bioelectronic medicine company that deploys implantable technology to supplant drugs, I wish he were wrong. But rampant misalignment of incentives is hampering technology in the U.S. health industry.
    Start with the Food and Drug Administration, which places the highest premium on "protecting the public health," according to the agency's website. The agency believes this goal is best accomplished through detailed oversight, ponderous review and ultimately control.
    Sergey Brin, CEO and co-founder of Google, has said regulatory burden dissuades a lot of entrepreneurs in the U.S. Reuters
    That doesn't work for entrepreneurs and investors, who want rapid returns on what they invest, at a pace faster than what the FDA allows. The pharmaceutical industry seeks large markets with high returns, and the major payers, including insurance providers, require evidence of cost effectiveness. Physicians and other prescribers have limited and dwindling resources to participate in research, and instead are encouraged to push standard treatment protocols, even when they are of questionable efficacy.
    And the public, the patients, and the parents and children of the suffering, want treatment to be available, immediate and cheap; free if possible.
    You don't need a postgraduate degree to realize the problem here. Members of Congress have proposed reforming the FDA in various ways, urging the agency to speed up its procedures. These are laudable efforts, but no government agency will ever be limber enough to mollify the Mr. Brins of this world.
    Which is why it's time to try a new solution. The government and entrepreneurs should be allowed to carve out their own turf and let patients choose their own level of risk.
    Consider the case of Goran Ostovich, a burly, 47-year-old truck driver from Mostar, Bosnia. Mr. Ostovich has suffered from long-standing rheumatoid arthritis and needed near-permanent bed rest. With his hands and wrists swollen and aching, he could no longer hold on to a wheel or even play with his small children. He tried a variety of medications. None worked.
    When I met Goran at his doctor's office in 2012, however, he didn't seem at all afflicted with the disease. That's because, one year earlier, he had been offered the opportunity to be the first participant in a clinical trial of a new therapy based on my invention. He received a bioelectronic implant and rapidly improved. His mobility restored, he was soon back at work and even sustained an exertion injury from playing tennis.
    Since news of this clinical trial's success became public, people from all over the U.S. stricken with rheumatoid arthritis have emailed, called and sent letters pressing for their shot at potentially effective—but not yet FDA-approved—treatments. Most wrote that they would gladly travel to Europe if it meant they could get access to the device.
    That's exactly the point: Some patients are very willing to take a calculated risk, but misaligned incentives in the industry are driving potential stakeholders with new solutions out of the business.
    While the FDA does a commendable job, there is no reason it should have the sole responsibility for access to lifesaving treatment. Institutional review boards and human-subject research protocols provide extremely high levels of protection overseeing clinical trials in the U.S. and Europe. These bodies have weeded out the charlatans in the industry, and the ultimate determinant of success will be patient satisfaction.
    Mr. Brin and his colleagues took Google public under atypical rules, and to much fanfare. It is time to apply this kind of boldness to realign bioelectronic medicine research with clinical needs. Our patients deserve no less.
    Dr. Tracey is a neurosurgeon and CEO of the Feinstein Institute for Medical Research at North Shore-LIJ Health System.





    Opinion

    Let Patients Decide How Much Risk They'll Take

    Take a tip from Sergey Brin: The health-care regulatory burden stops entrepreneurs from getting into the game.


    Updated July 27, 2014 6:44 p.m. ET
    Earlier this month, at a private conference for the CEOs of his portfolio companies, venture capitalist Vinod Khosla interviewed Google GOOGL +0.16% co-founders Sergey Brin and Larry Page, asking them if the company might jump into health care. "It's just a painful business to be in," Mr. Brin replied, later noting that "the regulatory burden in the U.S. is so high that I think it would dissuade a lot of entrepreneurs."
    Mr. Brin is right. As a neurosurgeon-scientist and entrepreneur who co-founded a bioelectronic medicine company that deploys implantable technology to supplant drugs, I wish he were wrong. But rampant misalignment of incentives is hampering technology in the U.S. health industry.
    Start with the Food and Drug Administration, which places the highest premium on "protecting the public health," according to the agency's website. The agency believes this goal is best accomplished through detailed oversight, ponderous review and ultimately control.
    Sergey Brin, CEO and co-founder of Google, has said regulatory burden dissuades a lot of entrepreneurs in the U.S. Reuters
    That doesn't work for entrepreneurs and investors, who want rapid returns on what they invest, at a pace faster than what the FDA allows. The pharmaceutical industry seeks large markets with high returns, and the major payers, including insurance providers, require evidence of cost effectiveness. Physicians and other prescribers have limited and dwindling resources to participate in research, and instead are encouraged to push standard treatment protocols, even when they are of questionable efficacy.
    And the public, the patients, and the parents and children of the suffering, want treatment to be available, immediate and cheap; free if possible.
    You don't need a postgraduate degree to realize the problem here. Members of Congress have proposed reforming the FDA in various ways, urging the agency to speed up its procedures. These are laudable efforts, but no government agency will ever be limber enough to mollify the Mr. Brins of this world.
    Which is why it's time to try a new solution. The government and entrepreneurs should be allowed to carve out their own turf and let patients choose their own level of risk.
    Consider the case of Goran Ostovich, a burly, 47-year-old truck driver from Mostar, Bosnia. Mr. Ostovich has suffered from long-standing rheumatoid arthritis and needed near-permanent bed rest. With his hands and wrists swollen and aching, he could no longer hold on to a wheel or even play with his small children. He tried a variety of medications. None worked.
    When I met Goran at his doctor's office in 2012, however, he didn't seem at all afflicted with the disease. That's because, one year earlier, he had been offered the opportunity to be the first participant in a clinical trial of a new therapy based on my invention. He received a bioelectronic implant and rapidly improved. His mobility restored, he was soon back at work and even sustained an exertion injury from playing tennis.
    Since news of this clinical trial's success became public, people from all over the U.S. stricken with rheumatoid arthritis have emailed, called and sent letters pressing for their shot at potentially effective—but not yet FDA-approved—treatments. Most wrote that they would gladly travel to Europe if it meant they could get access to the device.
    That's exactly the point: Some patients are very willing to take a calculated risk, but misaligned incentives in the industry are driving potential stakeholders with new solutions out of the business.
    While the FDA does a commendable job, there is no reason it should have the sole responsibility for access to lifesaving treatment. Institutional review boards and human-subject research protocols provide extremely high levels of protection overseeing clinical trials in the U.S. and Europe. These bodies have weeded out the charlatans in the industry, and the ultimate determinant of success will be patient satisfaction.
    Mr. Brin and his colleagues took Google public under atypical rules, and to much fanfare. It is time to apply this kind of boldness to realign bioelectronic medicine research with clinical needs. Our patients deserve no less.
    Dr. Tracey is a neurosurgeon and CEO of the Feinstein Institute for Medical Research at North Shore-LIJ Health System.


    Cell Mol Life Sci. 2005 Aug;62(16):1850-62.

    The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanistically based hypothesis.

    Abstract

    Excess levels of tumor necrosis factor-alpha (TNF-alpha) have been associated with certain autoimmune diseases. Under the rationale that elevated TNF-alpha levels are deleterious, several anti-TNF-alpha therapies are now available to block the action of TNF-alpha in patients with autoimmune diseases with a chronic inflammatory component to the destructive process. TNF-alpha antagonists have provided clinical benefit to many patients, but their use also is accompanied by new or aggravated forms of autoimmunity. Here we propose a mechanistically based hypothesis for the adverse events observed with TNF-alpha antagonists, and argue for the opposite therapeutic strategy: to boost or restore TNF-alpha activity as a treatment for some 
    forms of autoimmunity. Activation defects in the transcription factor nuclear factor kappaB leave autoreactive T cells sensitive to TNF-alpha-induced apoptosis. Treatment with TNF-alpha, by destroying autoreactive T cells, appears to be a highly targeted strategy to interrupt the pathogenesis of type 1 diabetes, lupus and certain forms of autoimmunity.


     see faustmanlab.org
    The Faustman Lab at Massachusetts General Hospital
    Denise Faustman, MD, PhD, is Director of the Immunobiology Laboratory at the Massachusetts General Hospital (MGH) and an Associate Professor of Medicine at Harvard Medical School. Her current research focuses on discovering and developing new treatments for type 1 diabetes and other autoimmune diseases, including Crohn's disease, lupus, scleroderma, rheumatoid arthritis, Sjögren's syndrome, and multiple sclerosis. She is currently leading a human clinical trial program testing the efficacy of the BCG vaccine for reversal of long-term type 1 diabetes. Positive results from the Phase I study were reported in 2012.